Cytochroma to present at upcoming investor conferences
MARKHAM, ON, Sept. 7, 2011 /PRNewswire/ - Cytochroma today announced that the Company will be presenting a corporate overview at the following investor conferences:
- Charles W. Bishop, Cytochroma's President and Chief Executive Officer will be presenting at the Stifel Nicolaus Healthcare Conference 2011 at 4:25 PM ET on Wednesday, September 7, 2011 at the Four Seasons Hotel in Boston.
- Eric J. Messner, Cytochroma's Chief Operating Officer will be presenting at the RW Baird 2011 Health Care Conference at 1:45 PM ET on Thursday, September 8, 2011 at The New York Palace Hotel in New York City.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio of CYP24 and phosphate-uptake inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.